News

Cresilon expands nationwide reach for VETIGEL through distribution agreements with Midwest Veterinary Supply, Victor Medical Company, and Penn Veterinary Supply NEW YORK (April 24, 2024) — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into distribution agreements for VETIGEL® to be sold through several leading regional distributors […]

Revolutionary hemostatic gel for veterinary surgeons now available through Covetrus, MWI Animal Health, and Patterson Veterinary Supply   NEW YORK (April 19, 2024) — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into distribution agreements for its revolutionary hemostatic gel, VETIGEL®, to be sold directly

Original news piece from Fast Company Cresilon’s hemostatic gel that can help blood clot without pressure has made it one of the most innovative medical device companies of 2024. Every year, about 1.5 million people worldwide die from blood loss. The problem is especially acute when the loss is caused by trauma, which has no

Cresilon Launches “VETIGEL Gives” to Sponsor Life-Saving Surgeries for Animals in Need   Company behind groundbreaking hemostatic technology launches animal philanthropy program at a time when nearly 30% of U.S. pet owners experience barriers to veterinary care   NEW YORK (March 13, 2024) — Cresilon Inc. (“Cresilon”), Brooklyn-based biotechnology company focused on hemostatic medical device

NEW YORK, Oct. 27, 2022 — Cresilon, Inc., the Brooklyn-based biotechnology company developing and manufacturing innovative hemostatic medical device technologies, today announced the successful completion of a $25 million Series A-4 financing round. The financing will support the company’s efforts to aggressively accelerate its global expansion plan and bring its revolutionary hemostatic gel to the human

NEW YORK, Sept. 27, 2022 — Cresilon, Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, has entered into a Cooperative Research and Development Agreement (“CRADA”) with Walter Reed Army Institute of Research (“WRAIR”), the largest biomedical research facility administered by the U.S. Department of Defense (“DoD”), to advance the development of medical